Quantcast

Latest Antibody Stories

2014-09-16 08:29:12

CAMBRIDGE, England, September 16, 2014 /PRNewswire/ -- Sphere Fluidics Limited has developed unique technology for single cell analysis and characterization and provides proprietary products and novel services for this rapidly-growing market. The Company has raised over $6 million to date. "We are starting to develop a brand new single cell analysis instrument called Cyto-Mine(TM) (see image below). This will be revolutionary for the Biopharmaceutical Discovery and...

2014-09-10 08:31:55

SAN DIEGO, Sept. 10, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: TELK), a clinical stage oncology drug development company, announced today it has entered into agreements with Memorial Sloan Kettering Cancer Center (MSK) and Juno Therapeutics (Juno) for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the Company's internally developed antibody discovery platform. Under the...

2014-09-09 08:32:54

Collaboration to Express Antibodies and Antigens based on Sutro's Technology Platform Xpress CF(TM) SAN FRANCISCO, Sept. 9, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced its collaboration with the laboratory of James Wells, Ph.D., professor and chair of the Department of Pharmaceutical Chemistry at UCSF, as part of the...

2014-09-08 16:25:41

Clinical testing volume and positivity rate both grew after the first case of the infectious disease spread to Western Hemisphere this year MADISON, N.J., Sept. 8, 2014 /PRNewswire/ -- A growing number of patients in the United States are being tested - and testing positive - for the mosquito-borne chikungunya virus, according to a study presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C. The study, by scientists from Quest Diagnostics...

2014-09-08 08:31:19

SHM-XEL Platform Successfully Generates Novel Therapeutic Approach to Autoimmune Disease SAN DIEGO, Sept. 8, 2014 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, has exercised its option to acquire a novel antibody program from AnaptysBio. Upon payment of an option exercise fee to...

2014-09-03 08:33:44

Experienced Financial and Operational Leader to Support Global Development of Novel Monoclonal Antibody Therapeutics to GPCRs LA JOLLA, Calif. and SHANGHAI, Sept. 3, 2014 /PRNewswire/ -- RuiYi, Inc., a global therapeutic innovation leader, announced today the appointment of Mark Saad as chief financial officer (CFO). Mr. Saad is a skilled financial and operations leader and was most recently CFO at Cytori Therapeutics for the past ten years. At RuiYi, he will play a critical...

2014-09-02 04:20:51

Goodwin Biotechnology pioneered best-in-class practices for the development of complex Biopharmaceuticals and Antibody Drug Conjugates (ADCs) LONDON, Sept. 2, 2014 /PRNewswire/ -- Based on its recent analysis of the mammalian contract manufacturing services market, Frost & Sullivan recognises Goodwin Biotechnology with the 2014 Global Frost & Sullivan Award for Customer Value Leadership. Goodwin Biotechnology's reputation as one of the most trusted providers of mammalian contract...

2014-08-28 12:29:01

Key Program Part of Recent Merger with MabVax Therapeutics, Inc. SAN DIEGO, Aug. 28, 2014 /PRNewswire/ -- Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has made significant progress related to the development of its lead antibody program designated 5B1. The fully-human antibody was recovered using the Company's internally developed antibody discovery platform. These...

2014-08-26 08:31:33

SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. As this disease progresses, scarring in the lungs increases and patients gradually lose...

2014-08-25 12:27:19

Robust antibody gives researchers early access to PD-L1 and immunotherapy tissue staining for Research Use Only (RUO) applications PLEASANTON, Calif., Aug. 25, 2014 /PRNewswire/ -- Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody(1). This new PD-L1 clone was developed for Roche/Genentech's anti-PD-L1 (MPDL3280A) immunotherapy development program and included in research of...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'